BioPharmSignal logoBioPharmSignal

Biotech News

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

Ocular Therapeutix (OCUL)Ocular TherapeutixCompany update

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.

Related news

OCULOcular Therapeutix2026-10-01 11:00 EST

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

OCULOcular Therapeutix2026-09-01 11:00 EST

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

OCGNOcugen2026-10-29 11:02 EST

Ocugen to Participate in Upcoming November Investor and Industry Conferences

OCGNOcugen2026-09-30 11:02 EST

Ocugen to Participate in Upcoming Scientific Conferences

EYPTEyePoint Pharmaceuticals2026-09-02 11:00 EST

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

TARSTarsus Pharmaceuticals2026-11-05 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

PRQRProQR Therapeutics2026-09-02 12:00 EST

ProQR to Participate in Upcoming Investor Conferences in September 2026

BLTEBelite Bio2026-09-01 12:00 EST

Belite Bio to Participate in Four Upcoming Investor Conferences

HROWHarrow, Inc.2026-09-01 11:00 EST

Harrow to Participate in Three Investor Conferences in September

OKYOOKYO Pharma2026-09-29 11:00 EST

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

View all latest news

Ocular Therapeutix

Sustained Ocular Drug Delivery Ocular Therapeutix develops bioresorbable hydrogel implants designed to deliver drugs within the eye for extended periods. Its lead franchise seeks to reduce the frequency of anti-VEGF injections for retinal vascular diseases. AXPAXLI AXPAXLI is an intravitreal hydrogel implant containing axitinib, a...

Recent company news

OCULOcular Therapeutix2026-11-06 12:00 EST

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCULOcular Therapeutix2026-11-02 12:00 EST

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

OCULOcular Therapeutix2026-10-29 11:00 EST

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

OCULOcular Therapeutix2026-10-09 11:00 EST

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCULOcular Therapeutix2026-10-01 11:00 EST

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

Stock data

Close
6.43 USD
Market cap
1.82B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States